CH EPL (R5)
1.0.0 - trial-use Switzerland flag

This page is part of the CH EPL (R5) (v1.0.0: DSTU 1) based on FHIR (HL7® FHIR® Standard) v5.0.0. This is the current published version. For a full list of available versions, see the Directory of published versions

Example RegulatedAuthorization: Reimbursement SL 17418

CH - EPL Reimbursement SL

  • FOPHDossierNumber: FOPH Dossier Number/17418
  • status: Reimbursed
  • statusDate: 2000-04-15
  • listingStatus: Listed
  • listingPeriod: 2000-04-15 --> (ongoing)
  • firstListingDate: 2000-04-15
  • costShare: 10
  • gamme: Transdermal

CH - EPL Product Price

  • value: CHF32.44 (CHF)
  • type: Ex-factory price
  • changeType: Price mutation after triennal review of pharmaceuticals
  • changeDate: 2014-11-01

CH - EPL Product Price

  • value: CHF53.65 (CHF)
  • type: Retail price
  • changeType: VAT-change
  • changeDate: 2024-01-01

subject: PackagedProductDefinition: identifier = http://fhir.ch/ig/ch-epl/sid/pcid#Clinical Product Identifier#CH-7601001029439-5470402-097; containedItemQuantity = 24 Patch; description = ESTALIS Matrixpfl 50/250 24 Stk

type: Reimbursement SL

Indications

-ExtensionReference
*ClinicalUseDefinition: type = indication

holder: Organization Sandoz Pharmaceuticals AG

Generated Narrative: Organization #holder-Sandoz-Pharmaceuticals-AG

identifier: LOC Identifier/100054743, GLN Identifier/7601001029439

name: Sandoz Pharmaceuticals AG